L
Lode J. Swinnen
Researcher at Johns Hopkins University
Publications - 169
Citations - 9691
Lode J. Swinnen is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Transplantation & Lymphoma. The author has an hindex of 49, co-authored 161 publications receiving 8473 citations. Previous affiliations of Lode J. Swinnen include United States Department of Veterans Affairs & Brown University.
Papers
More filters
Journal ArticleDOI
Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients.
Lode J. Swinnen,Costanzo-Nordin Mr,Susan G. Fisher,E J O'Sullivan,E J O'Sullivan,M R Johnson,M R Johnson,A L Heroux,A L Heroux,G J Dizikes,G J Dizikes,Roque Pifarré,Roque Pifarré,Richard I. Fisher,Richard I. Fisher +14 more
TL;DR: The addition of OKT3 to the immunosuppressive regimen increases the incidence of post-transplantation lymphoproliferative disorder after cardiac transplantation, and the risk increases sharply after cumulative doses greater than 75 mg.
Journal ArticleDOI
Epstein-barr virus-induced posttransplant lymphoproliferative disorders
Carlos V. Paya,John J. Fung,Michael A. Nalesnik,Elliott Kieff,Michael Green,Gregory J. Gores,Thomas M. Habermann,Russell H. Wiesner,Lode J. Swinnen,E. Steve Woodle,Jonathan S. Bromberg +10 more
TL;DR: This review summarizes the current knowledge of EBV-PTLD and, as a result of two separate international meetings on this topic, provides recommendations for future areas of study.
Journal Article
A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Michael Glantz,Michael Glantz,Kurt A. Jaeckle,Marc C. Chamberlain,Surasak Phuphanich,Lawrence Recht,Lode J. Swinnen,Bernard L. Maria,Susan LaFollette,G. Berry Schumann,Bernard F. Cole,Stephen B. Howell +11 more
TL;DR: In patients with solid tumor neoplastic meningitis, DepoCyt produced a response rate comparable to that of methotrexate and significantly increased the time to neurological progression while offering the benefit of a less demanding dose schedule.
Journal ArticleDOI
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.
Andrew D. Zelenetz,Jeremy S. Abramson,Ranjana H. Advani,Charalambos Andreadis,John C. Byrd,Myron S. Czuczman,Luis Fayad,Andres Forero,Martha Glenn,Jon P. Gockerman,Leo I. Gordon,Nancy L. Harris,Richard T. Hoppe,Steve Horwitz,Mark S. Kaminski,Youn H. Kim,Ann S. LaCasce,Tariq I Mughal,A P Nademanee,Pierluigi Porcu,Oliver W. Press,Leonard R. Prosnitz,Nishitha Reddy,Matthew R. Smith,Lubomir Sokol,Lode J. Swinnen,Julie M. Vose,William G. Wierda,Joachim Yahalom,Furhan Yunus +29 more
Journal ArticleDOI
Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis
Michael Glantz,Suzanne LaFollette,Kurt A. Jaeckle,William R. Shapiro,Lode J. Swinnen,Jack R. Rozental,Surasak Phuphanich,Lisa R. Rogers,John Gutheil,Tracy T. Batchelor,David Lyter,Marc C. Chamberlain,Bernard L. Maria,Charles Schiffer,Rifaat Bashir,David Thomas,Wayne Cowens,Stephen B. Howell +17 more
TL;DR: DepoCyt injected once every 2 weeks produced a high response rate and a better quality of life as measured by Karnofsky score relative to that produced by free ara-C injected twice a week.